Nina Capital

Marta G. Zanchi, the founder and managing partner, leads the investment team alongside general partner Marc Subirats and partners Sebastian Anastassiou and Yahel Halamish. The partnership group is supported by a network of external investment advisors and venture partners with deep health-tech and clinical backgrounds. Final investment decisions are made by this core team out of the firm's Barcelona headquarters.

No. The firm is explicit that it does not invest in drugs, vaccines, or traditional regulated medical devices. Its mandate is restricted to healthcare transformation powered by information technology — software, data platforms, and AI-native clinical tools. Founders building novel molecules or hardware-dependent Class III devices fall outside the firm's scope.

The firm invests across Europe, the United States, Israel, Canada, and Australia, with Europe serving as its operational and cultural home base. A US office on Page Mill Road in Palo Alto gives it direct proximity to Silicon Valley co-investors and portfolio companies. While the team is pan-regional in sourcing, its partnership meetings and core decision-making remain centralized in Barcelona.

The firm runs a structured internship and fellowship program that draws visiting analysts from top-tier technical and medical universities — including Stanford, Harvard, Cambridge, EPFL, Wharton, and IESE — with alumni placed across the global health-tech ecosystem. This academic network doubles as an early-warning sourcing engine for need-driven founders emerging from university labs and clinical settings. In addition, the firm's venture partners and investment advisors on the US coasts and in Milan extend its origination reach.

Yes. The firm states it can lead rounds and co-invest, with initial checks ranging from €200,000 to €1,500,000. As a preseed-to-seed+ investor, it typically takes a board observer or board seat when leading. Its ability to lead rounds in Europe and follow capital into the US gives it flexibility to set terms rather than always joining syndicates.

No. Nina Capital is a specialized venture capital firm, not a family office. It manages three closed-end venture capital funds as an authorized Alternative Investment Fund Manager (Nina Capital SGEIC, S.A.) regulated in Spain. The firm raises capital from external limited partners and deploys it through a dedicated institutional structure, not a single-family balance sheet.

Initial ticket sizes span €200,000 to €1,500,000. These are preseed and seed checks, with capacity to follow on in subsequent rounds. The wide range reflects the firm's willingness to anchor very early rounds in Europe or participate as a smaller co-investor in larger US-led seed syndicates, depending on the founder's need and the round composition.